<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
The Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported): March 3, 1997
ImmuLogic Pharmaceutical Corporation
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-19117 13-339757
- ----------------------- -------------------
(Commission File Number (I.R.S. Employer
Identification No.)
610 Lincoln Street
Waltham, Massachusetts 02154
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(617) 466-6000
- --------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
Not Applicable
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE> 2
Item 5. Other Events.
- ----------------------
On March 5, 1997, The Company announced a restructuring of its Board of
Directors. Five new members were appointed to the seven person Board of
Directors. They are J. Joseph Marr, M.D., acting President and Chief Executive
Officer of ImmuLogic; C. Garrison Fathman, M.D., Professor, Department of
Medicine and Immunology, Stanford University School of Medicine; Carl
Goldfischer, M.D., Chief Financial Officer, Vice President Finance and Strategic
Planning of ImClone Systems Incorporated; Geraldine Henwood, Chief Executive
Officer of IBAH, Inc.; and Richard Pops, Chief Executive Officer of Alkermes
Inc. These appointments followed the resignations of Malcolm Gefter, Ph.D.,
Chairman of the Board and scientific founder, Alan Dalby, Howard Jacobson,
Kenneth Melmon, M.D., and Larry Soll, Ph.D. Samuel Fleming, Chairman and Chief
Executive Officer of Decision Resources, Inc. and Paul Friedman, M.D., President
of Dupont Merck Research Labs, each of whom was appointed to the Board of
Directors in September 1996, will continue to serve as Directors.
The Company has entered into a severance agreement with Dr. Gefter
providing for payments to Dr. Gefter commensurate with those otherwise due under
his employment contract.
Item 7. Financial Statements and Exhibits
- ------------------------------------------
Exhibit
No. Description
--- -----------
99.1 Press Release dated March 5, 1997.
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: March 13, 1997 IMMULOGIC PHARMACEUTICAL
CORPORATION
/S/ John Morrison
------------------------------------
By: John Morrison
Title: Acting Chief Financial Officer
<PAGE> 4
Exhibit Index
-------------
Exhibit No. Exhibit
- ----------- -------
99.1 Press Release, dated March 5, 1997
<PAGE> 1
EXHIBIT 99.1
------------
FOR IMMEDIATE RELEASE
CONTACT: SUSAN PRIMROSE
DIRECTOR OF INVESTOR RELATIONS AND
CORPORATE COMMUNICATIONS
617-466-6000
IMMULOGIC RESTRUCTURES BOARD OF DIRECTORS
Waltham, MA (March 05, 1997): ImmuLogic Pharmaceutical Corporation
(Nasdaq:IMUL) today reported a restructuring of its Board of Directors. Five new
members have been appointed to the eight person Board of Directors, effective
immediately. They are J. Joseph Marr, M.D. acting President and Chief Executive
Officer of ImmuLogic; C. Garrison Fathman, M.D., Professor, Department of
Medicine, Stanford University School of Medicine; Carl Goldfischer, M.D., Chief
Financial Officer, Vice President Finance and Strategic Planning of ImClone
Systems Inc.; Geraldine Henwood, Chief Executive Officer of IBAH, Inc.; and
Richard Pops, Chief Executive Officer of Alkermes Inc. These appointments follow
the resignation of Malcolm Gefter, Ph.D., Chairman of the Board and scientific
founder, Alan Dalby, Howard Jacobson, Kenneth Melmon, M.D., and Larry Soll,
Ph.D. Two individuals, appointed to the Board in September 1996, will continue
as Directors, they are Samuel Fleming, Chairman and Chief Executive Officer of
Decision Resources, Inc. and Paul Friedman, M.D., President of Dupont Merck
Research Labs.
"This restructuring was done in consultation with several major
stockholders with the purpose of adding pharmaceutical and business advisory
capabilities to the Board. The newly constituted Board has the diversity of
talent and experience needed to guide ImmuLogic at its present stage of
development," said Dr. Joseph Marr, acting President and Chief Executive
Officer. "We thank the Board members who are stepping down for their
contributions to the company over the last several years. We would like
especially to acknowledge Dr. Malcolm Gefter for his scientific and business
contributions since he founded the Company in 1987."
The Company has entered into a severance agreement with Dr. Gefter
providing for payments commensurate with those otherwise due under his
employment contract.
ImmuLogic Pharmaceutical Corporation is a biopharmaceutical company,
located in Waltham, Massachusetts, specializing in the development of peptide
immunotherapeutics, with a primary focus on allergies, including cat and ragweed
allergies, and autoimmune diseases such as multiple sclerosis. The company also
is developing a cocaine vaccine. The company's press releases are available
through Company News on Call by fax at 800-758-5804, ext. 114501, and on the
Internet at www.prnewswire.com.
